Carmot Therapeutics focuses on innovative drug discovery and development, particularly targeting metabolic diseases such as obesity and diabetes. One of their key technologies is Chemotype Evolution, which allows for the systematic optimization of small molecules to enhance their therapeutic potential. This approach enables the identification of compounds that can effectively modulate biological pathways, thereby improving clinical outcomes for patients. Additionally, Carmot emphasizes the importance of Incretin Receptor Signaling Bias, which involves selectively activating specific signaling pathways to achieve desired therapeutic effects while minimizing side effects.

The company is dedicated to advancing its research through clinical trials and has a strong commitment to energy homeostasis, which is crucial for maintaining metabolic balance in individuals with metabolic disorders. By leveraging these technologies, Carmot Therapeutics aims to develop novel treatments that address the underlying mechanisms of metabolic diseases, ultimately contributing to a healthier future for patients. Their recent acquisition by Roche further enhances their capabilities and resources in the pursuit of these goals.

United States

Drug discovery and development to target the root causes that drive cancer and metabolic diseases using Chemotype Evolution.

Carmot Therapeutics

Company Details